Heart Blood Flow Imaging in Sickle Cell Disease Using PET Scans
Uses PET heart scans to study blood flow in young adults with sickle cell disease.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Registry title
- Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 10 Oct 2023
- Expected to end
- Sept 2028
- Type of study
- Interventional, 3 groups
- Treatments tested
- [13N]NH3
- Lexiscan
- Positron emission tomography
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Black people aged 18 to 21: those with sickle cell disease (with and without heart relaxation problems) and healthy controls. It studies blood flow to the heart under stress.
- Age
- 18 to 21 years
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of HbSS or HbSβ0thalassemia type. Stratum A has three or more abnormal diastolic heart measures. Stratum B has two or fewer. Healthy controls also have two or fewer.
- Earlier treatment
- People with sickle cell disease cannot join if they had a blood transfusion in the last 3 months.
- Biomarker or test result
- HbSS or HbSβ0thalassemia genotype for sickle cell patients. Healthy controls must not have any sickle cell genotype.
Main reasons for not taking part
- Recent hospital stay for a pain crisis or acute chest syndrome in the last 4 weeks (sickle cell groups)
- Blood transfusion in the last 3 months (sickle cell groups)
- Signs of acute heart damage, a heart attack, or unstable angina
- Previous heart surgery or serious heart rhythm problems
- Pregnant or breast-feeding
The registry criteria, word for word
Show all 58 criteriaShow less
Who can take part
- 18 to 21 years of age
- Black
- Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes
- Three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)
- 18 to 21 years of age
- Black
- Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes
- Two or less abnormal diastolic parameters
- 18 to 21 years of age
- Black
- Two or less abnormal diastolic parameters
Who cannot take part
- Previous cardiac surgery
- Previous cardiac surgery
- Previous cardiac surgery
- Recent hospitalization for vaso-occlusive pain crisis or acute chest syndrome in last 4 weeks
- Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina
- Individuals with history of VT/VF or SVT
- Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect)
- Stenotic valvular disease or left main coronary artery stenosis
- History of myo/pericarditis
- Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency)
- History of sinus node dysfunction or high grade AV nodal block
- History of aborted sudden cardiac death or cardiac arrest
- Current seizure disorder on AED
- Recent hospitalization for vaso-occlusive pain crisis or acute chest syndrome in last 4 weeks
- Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina
- Individuals with history of VT/VF or SVT
- Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect)
- Stenotic valvular disease or left main coronary artery stenosis
- History of myo/pericarditis
- Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency)
- History of sinus node dysfunction or high-grade AV nodal block
- History of aborted sudden cardiac death or cardiac arrest
- Current seizure disorder on AED
- Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina
- Individuals with history of VT/VF or SVT
- Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect)
- Stenotic valvular disease or left main coronary artery stenosis
- History of myo/pericarditis
- Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency)
- History of sinus node dysfunction or high-grade AV nodal block
- History of aborted sudden cardiac death or cardiac arrest
- Current seizure disorder on AED
- Blood transfusion in the last 3 months
- Left ventricle systolic dysfunction
- Pregnant/Breast-feeding
- Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised
- Diagnosed with three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)
- Blood transfusion in the last 3 months
- Left ventricle systolic dysfunction
- Pregnant/Breast-feeding
- Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised
- All genotypes of SCD
- Diagnosed with three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)
- Anemia of grade 2 or worse (per CTCAE v5.0) at study visit 1
- Left ventricle systolic dysfunction
- Pregnant/Breast- feeding
- Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 21 years old?
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Parul Rai, MDTaking people
About the trial
What the trial wants to find out
There is limited information on what causes injury to the heart in individuals with Sickle Cell Disease (SCD). Researchers in this study want to see if decreased blood flow to the heart during stress could be causing the heart damage seen in SCD patients. They also want to test people who don't have SCD to see if their hearts react the same way under stress.
Read full original descriptionShow less
Primary Objective
* To estimate the coronary flow reserve (CFR) (also referred to as myocardial perfusion reserve), as measured by PET stress-rest myocardial perfusion imaging, in SCD patients with and without diastolic dysfunction, and healthy controls.
Secondary Objectives
* To investigate the relationship between decreased CFR (quantified with PET stress- rest myocardial perfusion imaging) and presence of abnormal diastolic parameters
The 3 groups in the trial
- Stratum ATreatment being tested
Sickle Cell patients with diastolic dysfunction
Treatment: [13N]NH3, Lexiscan, and Positron emission tomography
- Stratum BTreatment being tested
Sickle cell patients without diastolic dysfunction
Treatment: [13N]NH3, Lexiscan, and Positron emission tomography
- Stratum CTreatment being tested
Healthy controls
Treatment: [13N]NH3, Lexiscan, and Positron emission tomography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Evaluation of the Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (Stress-Rest) Myocardial Perfusion Imaging (MYPERS)
- Plain-language title
- Heart Blood Flow Imaging in Sickle Cell Disease Using PET ScansGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05583721, who can take part
- Record updated
- 6 May 2026